Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004071 · ClinicalTrials.gov registry record · Phase 2
Mitoxantrone and Prednisone With or Without Leflunomide in Treating Patients With Stage IV Prostate Cancer
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00004071: Completed Phase 2 study, sponsored by Pfizer.
NCT00004071 is a Phase 2 study that has completed, run by Pfizer. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004071, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known if mitoxantrone and prednisone are more effective with or without leflunomide for treating prostate cancer. PURPOSE: Randomized phase II/III trial to compare the effectiveness of mitoxantrone and prednisone with or without leflunomide in treating patients who have stage IV prostate cancer that has not responded to hormone therapy.
Interventions
- DRUG prednisone
- DRUG mitoxantrone hydrochloride
- DRUG leflunomide
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-08 |
| Est. Completion | 2007-09 |
| Phase | Phase 2 |
What the finished NCT00004071 record still lists
NCT00004071 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which prednisone is the first listed.
NCT00004071 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00004071 about?
NCT00004071 is a clinical study titled "Mitoxantrone and Prednisone With or Without Leflunomide in Treating Patients With Stage IV Prostate Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known if mitoxantrone and prednisone are more effective with or without leflunomide for treating prostate canc...
What is the current status of trial NCT00004071?
This trial is currently completed. It is a Phase 2 study. The study started on 1999-08. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00004071?
The interventions under investigation include: prednisone (DRUG), mitoxantrone hydrochloride (DRUG), leflunomide (DRUG).
Who is sponsoring clinical trial NCT00004071?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia